<DOC>
	<DOCNO>NCT00883337</DOCNO>
	<brief_summary>Primary objective ass effectiveness evaluate time failure two dos teriflunomide comparison interferon beta-1a participant relapse Multiple Sclerosis [ MS ] . Secondary objective : - To assess effect two dos comparison interferon beta-1a : - Frequency relapse , - Fatigue , - Participant 's satisfaction treatment . - To evaluate safety tolerability two dos comparison interferon beta-1a . The study consist core treatment period common end date define 48 week randomization last participant , follow optional long-term extension treatment period teriflunomide commercially available accordance local regulation .</brief_summary>
	<brief_title>A Study Comparing Effectiveness Safety Teriflunomide Interferon Beta-1a Patients With Relapsing Multiple Sclerosis</brief_title>
	<detailed_description>The core treatment period per participant variable depend enrollment study ( maximum approximatively 118 week ) . The two dos teriflunomide administer double-blind fashion , whereas interferon beta-1a ( Rebif® ) open-label . The opportunity continue high dose teriflunomide open-label fashion offer participant successfully complete treatment core study . The overall treatment period follow 4-week elimination follow-up period .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<criteria>Relapsing form MS meeting McDonald 's criterion MS diagnosis Expanded Disability Status Scale [ EDSS ] score ≤5.5 screen visit . Significantly impaired bone marrow function , significant anemia , leukopenia thrombocytopenia ; Persistent significant severe infection . Liver function impairment know history hepatitis . Use adrenocorticotrophic hormone [ ACTH ] systemic corticosteroid 2 week prior randomization . Human immunodeficiency virus [ HIV ] positive . Prior use Rebif® , prior concomitant use interferon 3 month prior randomization . Prior concomitant use cladribine , mitoxantrone , immunosuppressant agent azathioprine , cyclophosphamide , cyclosporin , methotrexate , mycophenolate , natalizumab . Pregnant breastfeed woman . Extension criterion : The participant meet follow criterion end core study period eligible enrolment openlabel extension phase : Participants discontinue treatment core period minimum treatment 48 week complete EOT visit ( Visit 18 ) . Participants meet criterion treatment withdrawal . An informed consent must obtain write participant openlabel extension phase prior enter prior completion extension phase procedure . Participants demonstrate willingness ability roll extension phase opportunity continue treatment 14 mg/day teriflunomide openlabel . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Relapsing-remitting multiple sclerosis</keyword>
</DOC>